Author: admin

  • Britain sliding ‘into economic crisis’ over £85bn sickness bill

    Britain sliding ‘into economic crisis’ over £85bn sickness bill

    Emer MoreauBusiness reporter

    Getty Images A woman lying on her couch, apparently sick. She is holding a tissue and has a blanket covering her.Getty Images

    The report said that a 22-year-old who falls out of work for health reasons could lose out on £1m over the course of their lifetime.

    The number of sick and disabled people out of work is putting the UK is at risk of an “economic inactivity crisis” that threatens the country’s prosperity, according to a new report.

    There were 800,000 more people out of work now than in 2019 due to health conditions, costing employers £85bn a year, according to the review by former John Lewis boss Sir Charlie Mayfield.

    The problem could worsen without intervention, but Sir Charlie, who will lead a taskforce aimed at helping people return to work, said this was “not inevitable”.

    The move has been broadly welcomed, but some business groups said Labour’s Employment Rights Bill included some disincentives to hiring people with existing illnesses.

    One in five working age people were out of work, and not seeking work, according to the report, which was commissioned by the Department for Work and Pensions by produced independently.

    Without intervention, another 600,000 people could leave work due to health reasons by the end of the decade.

    Sir Charlie said sickness cost employers £85bn a year through issues including lost productivity and sick pay, but it also cost the broader economy.

    “For employers, sickness and staff turnover bring disruption, cost and lost experience,” he said. “For the country, it means weaker growth, higher welfare spending and greater pressure on the NHS”.

    Speaking to the BBC, he said that “on the whole, work and health are mutually reinforcing”.

    “So keeping people in work, keeping them active, actually helps them to stay healthier.”

    The state spends £212bn per year on illness-related inactivity, or nearly 70% of income tax, through lost output, increased welfare payments and additional burdens on the NHS.

    People could be encouraged to stay in work if health is viewed as “a shared responsibility between employers, employees and health services”, he said.

    ‘I want to find a job’

    Loz Sandom has mental and physical health conditions which has made it difficult to find a job, and the last time they worked was a year ago.

    “I am willing to do the work, and I want to. I want to find a job,” said the 28-year-old, who has a degree in illustration and has previously worked as a digital marketing executive.

    They said that part of the challenge was employers did not realised they had “a duty to provide reasonable adjustments.”

    A female presenting person with dark rimmed glasses, a nose piercing, and hooped earings, and shortish dark hair - they are sitting being interviewed in a computer room

    “It’s such a shame because they’re missing out on so many fantastic disabled people that can do fabulous jobs.

    “And I’m not blaming employers entirely. They need support as well,” Loz added. “There are things that can be put in place to help employers, help save people.”

    Responding to the report, the government announced a major partnership with over 60 companies, many of them large employers, to “tackle the rising tide of ill-health that is pushing people out of work”.

    The companies include Tesco, Google UK, Nando’s and John Lewis.

    Over the next three years, they will “develop and refine workplace health approaches” which aim to “reduce sickness absence, improve return-to-work rates, and increase disability employment rate”.

    The government is aiming to develop these changes into a voluntary certified standard by 2029.

    Speaking to the BBC, Work and Pensions Secretary Pat McFadden said the report was a “win-win for employees and employers because its’ aimed at keeping people with sickness issues or developing disability issues in work”.

    “That’s in the interests of employers because these are good experienced staff and it’s in the interests of employees too because most people want to stay in work if they possibly can.”

    The Resolution Foundation think tank’s chief executive Ruth Curtice said: “The review has accurately identified a culture of fear, a dearth of support and structural barriers to work as key challenges to overcome in turning the tide for Britain’s economic inactivity problem – which is currently trending in the wrong direction.”

    The CIPD, which represents HR professionals, welcomed the government’s vision for a preventative approach to illness in the workplace.

    But its chief executive Peter Cheese said: “The report’s success will depend on the extent to which these recommendations are understood by business in driving positive outcomes and backed by policy makers at a national and regional level.”

    The report comes as the government tries to move ahead with its Employment Rights Bill – which some businesses say will stifle growth.

    The proposed new law includes a right to guaranteed hours and cracks down on zero-hour contracts without the offer of work.

    As well as that bill, Chancellor Rachel Reeves is aiming to guarantee paid work to young people who have been out of a job for 18 months.

    Those who do not to take up the offer could face being stripped of their benefits.

    Continue Reading

  • Iranians commemorate anniversary of 1979 U.S. Embassy takeover at time of tensions

    Iranians commemorate anniversary of 1979 U.S. Embassy takeover at time of tensions

    TEHRAN, Iran — Iranians on Tuesday celebrated the anniversary of the 1979 takeover of the U.S. Embassy in Tehran — the first such commemoration since the U.S. bombed Iran’s nuclear facilities during a 12-day war with Israel in June.

    On Nov….

    Continue Reading

  • Swapping meat for plant-based options cuts fat but lowers protein, study finds

    Swapping meat for plant-based options cuts fat but lowers protein, study finds

    Swapping meat for plant-based or mycoprotein products reduces saturated fat and increases fiber, but these modest changes may not significantly improve cholesterol levels and could lead to a reduction in protein intake among key age…

    Continue Reading

  • Soil ‘memory’ can help plants respond to drought

    Soil ‘memory’ can help plants respond to drought

    New research has found that microbial communities in soil have the capacity to remember and adapt to past environmental events, helping plants to withstand drought…

    Continue Reading

  • Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025 USA – English APAC – Traditional Chinese APAC – English

    -Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts.

    -Phase Ib study data of ASC30 subcutaneous (SQ) injection showed that observed half-life reached 46 days for the treatment formulation (Injection A) and 75 days for the maintenance formulation (Injection B).

    -Combination of ASC47 and ASC31, a novel peptide agonist targeting both GLP-1R and GIPR, significantly outperformed both tirzepatide and ASC31 monotherapy in promoting weight loss, body fat loss, and muscle preservation in diet-induced obesity (DIO) mouse studies.

    -Presentations further highlight the promising efficacy and safety profiles of Ascletis’ diverse obesity pipeline and validate its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies.

    HONG KONG, Nov. 4, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces multiple poster presentations of the full analysis of the Phase Ib study of ASC30 once-daily oral tablet, Phase Ib study of ASC30 once-monthly injection, and preclinical study of the combination of ASC31 and ASC47 at ObesityWeek® 2025 in Atlanta, Georgia.

    Abstract Title: A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity

    Results:

    Efficacy: Body weight changes from baseline were 6.3% reduction (multiple ascending dose (MAD) 2, n=8, 40 mg), 4.3% reduction (MAD 1, n=7, 20 mg), and 0.2% increase (placebo, n=6). No plateau was observed at Day 29. Body weight change from baseline was 4.8% reduction for MAD 3 (n=7, 60 mg), with the maximum body weight change being 9.3% reduction in this cohort. Excluding two outliers, the mean body weight change from baseline was 5.9% reduction for MAD 3.

    GI Tolerability: In the MAD study, MAD 1 (20 mg cohort) showed no vomiting, while MAD 2 (40 mg cohort) had events. Titrating from 2 mg to 5 mg did not cause vomiting in MAD 1, but titrating from 2 mg to 10 mg did result in vomiting in MAD 2. Compared with MAD 2, MAD 3 showed no increasing trend in severity or incidence of gastrointestinal (GI) adverse events (AEs), despite two discontinuations due to principal investigator’s decisions, and one discontinuation due to subject withdrawal.

    Safety: No serious adverse events (SAEs) or Grade ≥ 3 AEs, including GI events, were observed. Labs, vitals, ECGs (QTc), and physical exams were normal. No hepatic safety signals were detected across all MAD cohorts.

    Conclusion: ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment. The highest dose level (MAD 3, 60 mg) exhibited up to 9.3% body weight reduction, showed no increasing trend in severity or incidence in GI AEs. ASC30 was safe and well tolerated with only mild-to-moderate GI AEs across all MAD cohorts. The safety profile of ASC30 tablets was consistent with or better than that of the GLP-1R agonist class.

    Abstract Title: ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity: A Ph Ib Study

    Results: The observed half-life (time for ASC30 concentrations to reduce to fifty percent (50%) of ASC30’s Cmax) reached 46 days and 75 days, for ASC30 subcutaneous (SQ) treatment formulation (Injection A) and ASC30 SQ maintenance formulation (Injection B), respectively. Cmax-to-Cday29 ratio of 1.5:1, supports ASC30 SQ treatment formulation monthly dosing, while Cmax-to-Cday85 ratio of 2.5:1, supports ASC30 SQ maintenance formulation quarterly dosing.

    No SAEs or Grade ≥ 3 AEs were observed. GI-related AEs were mild to moderate. Labs, vitals, ECGs (QTc), and physical exams were normal. No hepatic safety signals were detected across all cohorts.

    Conclusion: ASC30 ultra-long-acting, slow-release SQ depot formulations demonstrated 46-day observed half-life (treatment formulation) and 75-day observed half-life (maintenance formulation), supporting both once-monthly treatment and once-quarterly maintenance therapies.

    ASC30 SQ formulations were well tolerated, with only mild-to-moderate treatment-emergent adverse events (TEAEs), comparable or superior to those observed with GLP-1R agonists. Developed with Ascletis’ Ultra-Long-Acting Platform (ULAP) technology, ASC30 treatment and maintenance formulations represent a potential breakthrough in chronic weight management by improving treatment convenience, adherence, and quality of life.

    Abstract Title: GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice

    Results: The combination of ASC47 plus ASC31 resulted in a 44.8% reduction in weight compared to a 19.1% reduction for ASC31 monotherapy. This was a 134% greater reduction than ASC31 alone. The combination of ASC47 plus tirzepatide resulted in a 38.1% reduction in weight compared to a 20.4% reduction for tirzepatide alone. This was an 87% greater reduction in weight compared to tirzepatide alone. The mean greater reduction in weight of ASC31 in combination with ASC47 compared to ASC31 alone (134%) is statistically significantly higher than that of tirzepatide plus ASC47 compared to tirzepatide alone (87%).

    Conclusion: The combination of ASC47 and ASC31 significantly outperformed both tirzepatide and ASC31 monotherapy in promoting weight loss, body fat loss, and muscle preservation. The combination of ASC47 with either ASC31 or tirzepatide restored the body composition of obese mice to the level of healthy non-obese mice. ASC31 is a dual GLP-1R and GIPR peptide agonist. ASC47 is a small molecule thyroid hormone receptor beta (THRβ)-selective agonist and was designed with unique and differentiated properties to enable targeted delivery to adipose tissue.

    Detailed data presented at ObesityWeek® 2025 can be found at Ascletis’ website (link).

    “These presentations highlight the exciting efficacy and safety profiles of our diverse obesity pipeline of both small molecules and peptides and validate our proprietary AISBDD and ULAP technologies,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “As we advance clinical development of ASC30, ASC31, and ASC47, we remain focused on close discussion with strategic partners to ensure that Ascletis is best positioned to address the needs of patients with obesity globally.”

    About ASC30

    ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044 without patent extensions.

    About ASC31

    ASC31 is an in-house discovered and developed novel peptide agonist targeting both GLP-1R and GIPR, which demonstrated a favorable pharmacokinetic profile in non-human primates as well as promising in vitro activities and in vivo efficacy in the diet-induced obese (DIO) mice. ASC31 is part of Ascletis’ discovery efforts to apply its Ultra-Long-Acting Platform (ULAP) to in-house discovered novel subcutaneously (SQ) injectable peptides and oral peptides.

    About ASC47

    ASC47 is an adipose-targeted, once-monthly SQ injected THRβ-selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue.

    About Ascletis Pharma Inc.

    Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK). For more information, please visit www.ascletis.com.

    Contact:

    Peter Vozzo
    ICR Healthcare
    443-231-0505 (U.S.)
    [email protected]

    Ascletis Pharma Inc. PR and IR teams
    +86-181-0650-9129 (China)
    [email protected]
    [email protected]

    SOURCE Ascletis Pharma Inc.

    Continue Reading

  • Badlands’ Eyes $60 Million Global Box Office Opening

    Badlands’ Eyes $60 Million Global Box Office Opening

    At a time when the fall box office has hit the skids, Hollywood turns its weary eyes to a fanged, fleshy-headed alien to hopefully bail it out as 20th Century Studios’ Predator: Badlands is eyeing, on the low end, a $60 million global box…

    Continue Reading

  • Apple’s Live Translation on AirPods will finally reach the EU soon

    Apple’s Live Translation on AirPods will finally reach the EU soon

    When it announced the AirPods Pro 3 back in September, Apple also introduced Live Translation for them as well as the AirPods 4 with ANC and AirPods Pro 2. The feature works when the AirPods in question are paired with an Apple…

    Continue Reading

  • Live Updates: Magic-Hawks and Thunder-Clippers

    Live Updates: Magic-Hawks and Thunder-Clippers

    Shai Gilgeous-Alexander and the Thunder face the LA Clippers in the second half of our ‘NBA Coast 2 Coast’ doubleheader on NBC and Peacock.

    Enjoy the best of Tuesday’s six-game slate with the NBA.com live blog, featuring all of the…

    Continue Reading

  • Solar geoengineering in wrong hands could wreak climate havoc, scientists warn | Geoengineering

    Solar geoengineering in wrong hands could wreak climate havoc, scientists warn | Geoengineering

    Solar geoengineering could increase the ferocity of North Atlantic hurricanes, cause the Amazon rainforest to die back and cause drought in parts of Africa if deployed above only some parts of the planet by rogue actors, a report has warned.

    Continue Reading

  • How Is Hong Kong Dealing With Food Waste?

    How Is Hong Kong Dealing With Food Waste?

    Instead of disposing of it in landfills, food waste can be converted into energy and compost through proper treatment and processing. Two plants in Hong Kong are doing just that. 

    Managing food waste in Hong Kong is challenging. Currently, the recycling rate of food waste is low, and most of it is disposed of in landfills – which, however, are reaching their full capacities. What’s more, landfill operations have significant environmental impacts. For example, landfill gas, which primarily consists of methane and carbon dioxide, is a major contributor to global warming and poses a risk of gas explosions. Moreover, landfill leachate can contaminate groundwater and soil when liquids percolate through the solid waste.

    In 2023, more than one million tonnes of food waste – approximately 3,200 tonnes per day – were disposed of in Hong Kong’s landfills, accounting for 29% of the total municipal solid waste. 63% of the total was produced by domestic households and 37% came from commercial and industrial sectors.

    Food waste is, in fact, organic and biodegradable – and there are more efficient ways of disposing of it. One is composting, and the other is converting it into energy. 

    Currently, Hong Kong has two food waste recycling facilities: the Organic Resources Recovery Centre Phase 1 (O·Park1) in Siu Ho Wan, North Lantau, and Phase 2 (O·Park2) in Sha Ling, North District. They can treat 200 tonnes and 300 tonnes of food waste per day, respectively.

    The plants convert food waste into biogas – a renewable energy source that can replace fossil fuels like natural gas and crude oil – for electricity generation. The residues from the process can also be produced as compost for landscaping and agriculture use.

    Waste-to-Energy Process

    The waste-to-energy process is straightforward. First, the food waste undergoes pre-treatment, such as the addition of water and removal of impurities. Then, the treated food waste undergoes anaerobic digestion, a biochemical process where anaerobic bacteria break down organic matter in an environment without oxygen. This process has two end products: biogas and digestate. While biogas is useful for generating heat and electricity, the digestate can be further processed for composting. 

    Organic Resources Recovery Centre Phase 2 (O·PARK2) in Hong Kong. Photo: Environmental Protection Department.

    Electricity Generation

    Biogas can be used as a fuel in combined heat and power (CHP) units. After proper treatment, the gas can be combusted to turn the generator to produce electricity. The electricity supports the operation of the recycling facility and achieves self-sustaining operation. The surplus electricity is exported to the power grid. 

    It is estimated that O·Park1 and O·Park2 can support the electricity consumption of 3,000 and 5,000 households annually, respectively. At the same time, heat recovery devices are used to capture heat from the CHP system and support the facility’s heating demand.

    Composting

    The wet material left over from anaerobic digestion is called digestate. It can be turned into compost after dewatering and further degradation. The compost is rich in nutrients and able to improve soil fertility, making it suitable for planting. 

    O·Park1 hosts a rooftop farm, O·Farm, demonstrating the application of compost in agriculture. In each harvesting season, O·Park1 donates the harvested crops to food donation organizations or distributes the crops to the community through educational and public events.

    Currently, the public can redeem 100 grams of the compost via an app or schedule a visit to O·Park1 and bring their own container to collect the free compost. Government departments, schools, and organizations can apply for free compost by submitting an application form to the EPD.

    Food Waste Recycling Policies

    To increase food waste recycling rates in Hong Kong, the Environmental Protection Department (EPD) has been installing food waste recycling bins in public rental housing estates, private housing estates, and various recycling stations. 

    In 2020, it implemented the GREEN$ Electronic Participation Incentive Scheme. The public can download a mobile app and earn points by recycling waste at the EPD’s recycling facilities. The points can be redeemed for gifts like daily necessities, or can be used for shopping at supermarkets and retail stores. Residents can earn a maximum of 50 points per day for recycling food waste. 

    Smart Food Waste Bin at ground floor of Oi Yee House Yau Oi Estate, Tuen Mun, Hong Kong.
    Smart food waste bin at Oi Yee House Yau Oi Estate, Tuen Mun. Photo: Wikimedia Commons.

    Recent research by the Hong Kong University of Science and Technology suggests that since late 2023, public housing achieved complete coverage with smart bins, while collection points saw an 81% jump, and private housing bins surged by 230%. This push led to household recycling increasing fivefold, alongside a 50% increase in the volume of daily food waste collected.

    As announced in the Chief Executive’s 2025 Policy Address, unveiled in September, the government is planning to keep expanding the food waste recycling network in residential areas, aiming at having at least one food waste recycling bin in each block of public rental housing estates by 2026. But the same research suggests that the goal has yet to be met, with private estates lagging significantly “due to complex application procedures.”

    The EPD has also been providing free food waste collection services for commercial and industrial sectors since 2021. Premises producing a large amount of food waste, such as shopping malls and food factories, can contact the EPD to apply for food waste recycling bins. The EPD will arrange designated trucks to collect food waste on a daily basis. The department has also set up food waste recycling points at over 100 public refuse collection points and various temporary food waste recycling spots at fixed hours and locations every night.

    The collected food waste is sent to O·Park1 and O·Park2 to be turned into biogas through a process known as for anaerobic digestion. The biogas is then used to generate electricity.

    To further enhance Hong Kong’s food waste treatment capacity, the EPD has collaborated with the Drainage Services Department (DSD) to implement the Food Waste/Sludge Anaerobic Co-digestion Trial Scheme. Under the trial, which was implemented in 2019, a maximum of 50 tonnes of food waste per day is delivered to the sewage treatment plant for co-digestion with sewage sludge instead of being sent to landfills. 

    While the EPD handles the food waste pre-treatment and transportation processes, the DSD manages the co-digestion and energy recovery processes. The biogas generated for electricity generation is used to power the sewage treatment facilities’ internal power combustion, according to the scheme’s website.

    Currently, co-digestion operations take place in Tai Po Sewage Treatment Works and Sha Tin Sewage Treatment Works. 

    Alternatives

    While food waste recycling can transform waste into energy and compost, it is not a perfect long-term solution. Although the food waste recycling rate in Hong Kong has increased from 2% in 2018 to 6% in 2022, it remains very low. The root problem cannot be solved until households and business sectors change their habits and continue to create and dispose of food waste in rubbish bins. Complementary management strategies such as reducing food waste at the source and promoting food donations should thus also be part of the solution. 

    To reduce food waste at the source, the EPD suggests checking home food stocks to avoid over-purchasing, paying attention to expiration dates, properly storing food to prevent spoilage, and cooking or ordering a reasonable amount of food to minimize leftovers.

    At the same time, businesses such as restaurants and canteens can consider donating surplus food when the hygiene conditions allow. Currently, Hong Kong has 17 charitable organizations that provide food donation services. They collect the surplus food, ensure food safety and quality, prepare meals, and redistribute them to people in need.

    Featured image: Wikimedia Commons.

    More on the topic: 11 Effective Solutions for Food Waste

    Continue Reading